KR20110063479A - 치환된 트리아졸로-피리다진 유도체 - Google Patents

치환된 트리아졸로-피리다진 유도체 Download PDF

Info

Publication number
KR20110063479A
KR20110063479A KR20117006632A KR20117006632A KR20110063479A KR 20110063479 A KR20110063479 A KR 20110063479A KR 20117006632 A KR20117006632 A KR 20117006632A KR 20117006632 A KR20117006632 A KR 20117006632A KR 20110063479 A KR20110063479 A KR 20110063479A
Authority
KR
South Korea
Prior art keywords
compound
composition
deuterium
compounds
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR20117006632A
Other languages
English (en)
Korean (ko)
Inventor
스코트 하베슨
Original Assignee
콘서트 파마슈티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 콘서트 파마슈티컬즈, 인크. filed Critical 콘서트 파마슈티컬즈, 인크.
Publication of KR20110063479A publication Critical patent/KR20110063479A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR20117006632A 2008-08-29 2009-08-28 치환된 트리아졸로-피리다진 유도체 Ceased KR20110063479A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9329308P 2008-08-29 2008-08-29
US61/093,293 2008-08-29

Publications (1)

Publication Number Publication Date
KR20110063479A true KR20110063479A (ko) 2011-06-10

Family

ID=41721962

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20117006632A Ceased KR20110063479A (ko) 2008-08-29 2009-08-28 치환된 트리아졸로-피리다진 유도체

Country Status (17)

Country Link
US (4) US8003646B2 (https=)
EP (2) EP2328414B1 (https=)
JP (3) JP5183808B2 (https=)
KR (1) KR20110063479A (https=)
CN (2) CN104098578A (https=)
AU (1) AU2009285533B2 (https=)
BR (1) BRPI0912928A2 (https=)
CA (1) CA2735549A1 (https=)
DK (1) DK2328414T3 (https=)
EA (1) EA020071B1 (https=)
ES (1) ES2451542T3 (https=)
HR (1) HRP20140195T1 (https=)
MX (1) MX2011002278A (https=)
PL (1) PL2328414T3 (https=)
PT (1) PT2328414E (https=)
WO (1) WO2010025407A1 (https=)
ZA (1) ZA201102123B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2735549A1 (en) 2008-08-29 2010-03-04 Concert Pharmaceuticals, Inc. Substituted triazolo-pyridazine derivatives
EP2340782A4 (en) 2008-10-03 2014-04-02 Inst Alberto Luiz Coimbra De Pos Graduacao E Pesquisa De Engenharia Coppe Ufrj METHOD AND DEVICE FOR REMOVING METAL FRAGMENTS AND METAL ELEMENTS FROM TOOTH ROOT CHANNELS
US8501738B2 (en) 2009-06-23 2013-08-06 Concert Pharmaceuticals, Inc. Substituted triazolo-pyridazine derivatives
RU2014120166A (ru) 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
EP2768834B1 (en) * 2011-10-20 2016-04-27 Glaxosmithkline LLC Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
EP2802569B1 (de) 2012-01-11 2016-01-06 Bayer Intellectual Property GmbH Tetrazol-5-yl- und triazol-5-yl-arylverbindungen und ihre verwendung als herbizide
US20150158870A1 (en) * 2012-05-11 2015-06-11 Concert Pharmaceuticals Inc. Polymorphs of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
EP2847195A1 (en) * 2012-05-11 2015-03-18 Concert Pharmaceuticals Inc. Form 2 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
US20150099753A1 (en) * 2012-05-11 2015-04-09 Concert Pharmaceuticals Inc. Form 5 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
WO2015052173A1 (en) 2013-10-10 2015-04-16 Basf Se Tetrazole and triazole compounds and their use as herbicides
WO2015052178A1 (en) 2013-10-10 2015-04-16 Basf Se 1,2,5-oxadiazole compounds and their use as herbicides
WO2015095549A1 (en) * 2013-12-18 2015-06-25 Concert Pharmaceuticals, Inc. Dosage regimen for gabaa receptor subtype selective drug
US10166183B2 (en) 2014-02-07 2019-01-01 Auspex Pharmaceuticals, Inc. Pharmaceutical formulations
CN104353078B (zh) * 2014-11-24 2017-10-24 王寿世 一种麻醉用药物组合物
CN104474549A (zh) * 2014-11-24 2015-04-01 王寿世 异丙酚和gabaa受体拮抗剂在制备麻醉药物中的用途
US10026332B1 (en) 2017-04-10 2018-07-17 Jasmine Gupta Method to deliver contextual educational information utilizing smart wearables
SG11202109526PA (en) * 2019-03-18 2021-10-28 Neurocycle Therapeutics Inc Use of gabaa receptor modulators for treatment of pain
WO2023205722A1 (en) * 2022-04-20 2023-10-26 Engrail Therapeutics, Inc. Gabaa receptor modulator salts, particles, and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321162D0 (en) 1993-10-13 1993-12-01 Boots Co Plc Therapeutic agents
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
ES2194205T3 (es) * 1996-07-25 2003-11-16 Merck Sharp & Dohme Derivados de triazolo-piridazina sustituidos como ligandos para los receptores gaba.
YU43800A (sh) * 1998-01-21 2002-12-10 Merck Sharp & Dohme Limited Triazolo-piridazin derivati kao ligandi za gaba receptore
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
JP2002535407A (ja) * 1999-01-27 2002-10-22 メルク シャープ エンド ドーム リミテッド Ｇａｂａ受容体のリガンドとしてのトリアゾロピリダジン誘導体
PT1104760E (pt) 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
US20020165217A1 (en) * 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
DE60315876T2 (de) * 2002-11-28 2008-05-21 Neurosearch A/S Verfahren zum screening für verbindungen mit sedativer oder anxiolytischer potenz
WO2006061428A2 (en) 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
CN101309917B (zh) 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
US20080051422A1 (en) * 2006-08-22 2008-02-28 Concert Pharmaceuticals Inc. 4-Aminoquinazoline derivatives and methods of use thereof
WO2008030382A1 (en) 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US20080242687A1 (en) * 2007-04-02 2008-10-02 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
CA2735549A1 (en) 2008-08-29 2010-03-04 Concert Pharmaceuticals, Inc. Substituted triazolo-pyridazine derivatives

Also Published As

Publication number Publication date
CN104098578A (zh) 2014-10-15
HRP20140195T1 (hr) 2014-04-11
EP2328414A4 (en) 2011-11-16
ES2451542T3 (es) 2014-03-27
JP2012501346A (ja) 2012-01-19
WO2010025407A1 (en) 2010-03-04
EP2328414A1 (en) 2011-06-08
CN102176826A (zh) 2011-09-07
US8003646B2 (en) 2011-08-23
EP2716158A1 (en) 2014-04-09
EA201100409A1 (ru) 2011-10-31
US20100056529A1 (en) 2010-03-04
DK2328414T3 (en) 2014-03-10
JP5373982B2 (ja) 2013-12-18
EP2328414B1 (en) 2013-12-11
US20150111895A1 (en) 2015-04-23
AU2009285533A2 (en) 2011-04-21
US8399467B2 (en) 2013-03-19
JP2013100322A (ja) 2013-05-23
US8921366B2 (en) 2014-12-30
CN102176826B (zh) 2014-08-20
AU2009285533B2 (en) 2014-02-13
PL2328414T3 (pl) 2014-05-30
BRPI0912928A2 (pt) 2015-08-04
US20130225590A1 (en) 2013-08-29
US20120004236A1 (en) 2012-01-05
JP5183808B2 (ja) 2013-04-17
CA2735549A1 (en) 2010-03-04
MX2011002278A (es) 2011-04-14
EA020071B1 (ru) 2014-08-29
AU2009285533A1 (en) 2010-03-04
JP2014058518A (ja) 2014-04-03
PT2328414E (pt) 2014-03-17
ZA201102123B (en) 2011-12-28

Similar Documents

Publication Publication Date Title
KR20110063479A (ko) 치환된 트리아졸로-피리다진 유도체
US20190308976A1 (en) Deuterated derivatives of ruxolitinib
JP6261580B2 (ja) 重水素化イブルチニブ
US20110082147A1 (en) Substituted imidazotriazines
US20090005394A1 (en) Endothelin receptor antagonists
US10357499B2 (en) Substituted triazolobenzodiazepines
WO2009128947A1 (en) Piperazine derivatives
US8557815B2 (en) Substituted triazolophthalazine derivatives
KR102433283B1 (ko) 룩소리티닙의 중수소화된 유도체
US20090197899A1 (en) 3-(Dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide Derivatives and Methods of Use
WO2009099620A1 (en) 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
WO2010002451A1 (en) Naphthyridin derivatives
AU2014202485A1 (en) Substituted triazolo-pyridazine derivatives

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110322

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140827

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160321

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160830

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160321

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I